# Natalie Pankova

> Natalie Pankova is a seed investor at Zinc backing Therapeutics. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: Zinc
- Location: London, United Kingdom
- Total investments: 2
- Last investment: Mar 2026
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/natalie-pankova-phd-028a3a34/
- X (Twitter): https://twitter.com/ThisIsDrNatalie

Natalie Pankova is a seed investor at Zinc in London focused on Therapeutics and Biotechnology. Dr Natalie Pankova is the Chief Operating Officer at Metadvice, a digital health startup building artificial intelligence - driven clinical decision software to enable doctors and pharma executives combine the avalanche of newly available medical information into real time decision making. Dr Pankova holds a PhD from the Faculty of Medicine,University of Toronto, has worked as a scientist and executive in pharma, biotech and healthtech companies. She has led operations in drug discovery and development, health technology and machine learning, building novel technologies from the ground up, and understands the massive problems facing the healthcare landscape, the ways that technology is poised to challenge the status quo of these systems, and the complex journeys startups face in this space. She previously led healthcare efforts at the Government Blockchain Association in the UK, participated in technology initiatives within the Pharmaceutical Users Exchange Group (PhUSE), All-Party Parliamentary Groups at the UK Parliament, Research Data Alliance, and the British Standards Institute. She is a Digital Health Expert at the World Health Organization, an Associate Lecturer at Claude Littner Business School, and is on the Editorial Board of Frontiers in Blockchain Journal, as well as an Advisor and Mentor to early stage innovative startups.

## Contacts

5 contacts available for Natalie Pankova: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/dr-natalie-pankova?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 100% |
| Biotechnology | 2 | 100% |
| Health Care | 1 | 50% |
| Pharmaceutical | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Pre-Seed | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 1 | 50% |
| United Kingdom | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SignaCor | SignaCor is a clinical-stage biotech company exploring therapeutics for cardiac disorders, specifically hypertrophic cardiomyopathy. | $331.9K | Seed | Mar 09, 2026 | https://signacor.co.uk |
| Cellestial Health | Cellestial Health creates best-in-class, safe small molecule medicines that protect often-overlooked networks of brain cells known as astrocytes, halting the progression of Parkinson's disease and other neurological illnesses. | $656.3K | Pre-Seed | Dec 06, 2024 | https://cellestialhealth.com |

2 of 2 investments shown.

## Co-investors
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund, 1 deal together

## About Zinc

VC Fund · London, United Kingdom

Zinc builds new tech companies that solve the developed world’s toughest social issues. Learning from the successful innovation systems in computer and life sciences, Zinc combines insights from social sciences with top entrepreneurial talent and venture capital to build new, scalable, mission-led businesses. The Zinc Programme brings together 50bright minds for 6 months to find their co-founders and build new commercial businesses from scratch.

5 contacts available at Zinc.

| Name | Title | Profile |
| --- | --- | --- |
| Alex Wilding | Cohort 4 Founder | — |
| Ella Goldner | Co-founder and General Manager | — |
| Paul Kirby | Co-founder & CEO | — |
| Rachel Carey | Chief Scientist | — |
| Adrian Alexa | Fellow | — |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Natalie Pankova invest in?

Natalie Pankova invests primarily in Therapeutics, Biotechnology and Health Care startups, most often at Seed and Pre-Seed stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Natalie Pankova?

Public channels for Natalie Pankova include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Natalie Pankova last invest?

The most recent investment recorded for Natalie Pankova closed in Mar 2026. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co